STOCK TITAN

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date

BioLineRx (BLRX) will release its unaudited third-quarter 2026 financial results on November 23, 2026, before U.S. markets open. The quarter ended September 30, 2026. Chief Executive Officer Philip Serlin will speak on the 8:30 a.m. EST conference call that day.

The company’s event page will carry a live webcast, with a replay available approximately two hours after the call ends. A separate dial-in replay will be available through November 25, 2026.

Loading...
Loading translation...

Key Figures

Results release date: November 23, 2026
Results release date
November 23, 2026
Third-quarter 2026 unaudited financial results; before U.S. markets open

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Management to Hold Conference Call at 8:30 a.m. EST

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2026 on Monday, November 23, 2026, before the U.S. markets open.

BioLineRx Ltd. Logo

The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

CONTACTS:

United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2026-results-on-november-23-2026-302943733.html

SOURCE BioLineRx Ltd.

Keep reading